EGFR-IN-8

Research use only, not for human use.

EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.

EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.(In Vitro):In A549, PC9, H1975, CL68, and CL97?cells, EGFR-IN-8 (0-0.6 μM; 48 hours) suppresses the expression of EGFR and c-Met in these five cell lines irrespective of their mutational status. EGFR-IN-8 (0-20 μM; 24, 48, 72 hours) exhibits a time- and dose-dependent inhibitory effect on the viability of A549, PC9, H1975, CL68, and CL97?cells at different time intervals, with IC50 values ranging from 0.3 to 0.6?μM and 0.2-0.5?μM after 48 and 72?h of treatment respectively.(In Vivo):EGFR-IN-8 (50,150?mg/kg; oral gavage) exhibits suppression (29% and 60%, respectively) of H1975 xenograft tumor growth in a dose-dependent manner.

——

Angiogenesis

EGFR

——

——

——

2407957-87-1

662.0

C32H23ClF3N7O4

>98% (HPLC)

——

FC(F)(F)c1cc(NC(=O)Nc2cccc(c2)-c2nc(no2)-c2ccc(NC(=O)c3cccnc3)cc2Cl)ccc1NC(=O)C1CC1

——

(-20℃)

With Ice Pack

≥ 2 years